MicroRNAs and adipocytokines: Promising biomarkers for pharmacological targets in diabetes mellitus and its complications
- PMID: 28747014
- DOI: 10.1016/j.biopha.2017.07.059
MicroRNAs and adipocytokines: Promising biomarkers for pharmacological targets in diabetes mellitus and its complications
Abstract
Nowadays, diabetes mellitus (DM) along with its complications is considered as a fundamental problem in both developing and industrial countries, and is causing millions of people to suffer worldwide. Currently, diabetes mellitus is diagnosed traditionally or classically in the world by measuring fasting blood glucose and conducting oral glucose tolerance test. New alternatives are required for the treatment of diabetes mellitus, especially type 2 diabetes mellitus (T2DM), at its early levels due to the ineffective control of its development in patients. In recent years, by further identifying of molecular agents such as microRNAs (miRNAs), studies have focused on miRNAs in diabetes as well as in other diseases. These small non-coding RNA molecules have a significant role in the regulation of insulin gene expression and also, obesity problems. White adipose tissue, as an important tissue in obese subjects, is directly related to type 2 diabetes and its complications via synthesis of adipokines. Prevention and treatment of obesity should be noted since childhood. Our aim in this review is to briefly provide a new glance at types of potential biomarkers, which can be used as pharmacological targets for prevention and treatment of prediabetic subjects, and patients with T2DM.
Keywords: Adipocytokine; MicroRNA; Obesity; Pharmacological target.
Copyright © 2017. Published by Elsevier Masson SAS.
Similar articles
-
Pancreas-enriched miRNAs are altered in the circulation of subjects with diabetes: a pilot cross-sectional study.Sci Rep. 2016 Aug 25;6:31479. doi: 10.1038/srep31479. Sci Rep. 2016. PMID: 27558530 Free PMC article.
-
Profiling peripheral microRNAs in obesity and type 2 diabetes mellitus.APMIS. 2015 Jul;123(7):580-5. doi: 10.1111/apm.12389. Epub 2015 Apr 24. APMIS. 2015. PMID: 25912229
-
Significance of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: a clinical study.Acta Diabetol. 2011 Mar;48(1):61-9. doi: 10.1007/s00592-010-0226-0. Epub 2010 Sep 21. Acta Diabetol. 2011. PMID: 20857148
-
Significance of circulating microRNAs in diabetes mellitus type 2 and platelet reactivity: bioinformatic analysis and review.Cardiovasc Diabetol. 2019 Aug 30;18(1):113. doi: 10.1186/s12933-019-0918-x. Cardiovasc Diabetol. 2019. PMID: 31470851 Free PMC article. Review.
-
Role of microRNAs in regulation of insulin secretion and insulin signaling involved in type 2 diabetes mellitus.J Biosci. 2022;47:36. J Biosci. 2022. PMID: 36222140 Review.
Cited by
-
The Pathophysiological Role of CoA.Int J Mol Sci. 2020 Nov 28;21(23):9057. doi: 10.3390/ijms21239057. Int J Mol Sci. 2020. PMID: 33260564 Free PMC article. Review.
-
Metabolic Dysfunction Biomarkers as Predictors of Early Diabetes.Biomolecules. 2021 Oct 27;11(11):1589. doi: 10.3390/biom11111589. Biomolecules. 2021. PMID: 34827587 Free PMC article. Review.
-
An update on mode of action of metformin in modulation of meta-inflammation and inflammaging.Pharmacol Rep. 2022 Apr;74(2):310-322. doi: 10.1007/s43440-021-00334-z. Epub 2022 Jan 24. Pharmacol Rep. 2022. PMID: 35067907 Review.
-
Current Trends on Innovative Technologies in Topical Wound Care for Advanced Healing and Management.Curr Drug Res Rev. 2024;16(3):319-332. doi: 10.2174/0125899775262048230925054922. Curr Drug Res Rev. 2024. PMID: 37807417 Review.
-
Endogenous and microbial biomarkers for periodontitis and type 2 diabetes mellitus.Front Endocrinol (Lausanne). 2023 Dec 5;14:1292596. doi: 10.3389/fendo.2023.1292596. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 38149100 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical